Founded with a mission to transform the treatment landscape for rare dermatological diseases, NFlection Therapeutics is a clinical-stage biopharmaceutical company. The company's core vision is to develop targeted therapies for conditions driven by aberrant activation of the RAS pathway, including neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection focuses on creating novel, topical treatments to meet the unmet needs of patients suffering from these rare disorders.

NFlection Therapeutics has garnered attention through its innovative approach and significant progress in clinical trials. The company has attracted notable investors and collaborators from the biopharmaceutical industry, enhancing its research and development capabilities. Key achievements include advancing its pipeline of therapies into clinical stages and demonstrating promising results in early trials. NFlection's impact lies in its potential to offer effective, targeted treatments for patients with limited options, thereby improving their quality of life and addressing critical gaps in dermatological care.